Prediction of radiation pneumonitis: Dose-volume histogram analysis in 62 patients with non-small cell lung cancer after three-dimensional conformal radiotherapy

Neoplasma

Volumn 52, Issue 1, 2005, Pages 56-62

  Piotrowski, T ^a   Matecka Nowak, M ^a   Milecki, P ^a  

^a Greatpoland Cancer Center   (Poland)

Author keywords

Dose volume histogram; NSCLC; Radiation pneumonitis; Radiotherapy

Indexed keywords

ADULT; ARTICLE; CANCER RADIOTHERAPY; COLLIMATOR; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; DOSE VOLUME HISTOGRAM; FEMALE; FOLLOW UP; HISTOGRAM; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; RADIATION DOSE; RADIATION PNEUMONIA; THORAX RADIOGRAPHY; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME;

EID: 14744269849     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. ARMSTRONG J, McGIBNEY C. The impact of three-dimensional radiation on the treatment of non-small cell lung cancer. Radiother Oncol 2000; 56(2): 157-167.
2. ARMSTRONG JG, ZELEFSKY MJ, LEIBEL SA, BURMAN C, HAN C et al. Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer. Ann Oncol 1995; 6(7): 693-697.
3. ARRIAGADA R, LE CHEVALIER T, QUOIX E, RUFFIE P, DE CREMOUX H et al. ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys 1991; 20(6): 1183-1190.
4. BRADLEY JD, IEUMWANANONTHACHAI N, PURDY JA, WASSERMAN TH, LOCKETT MA et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformai radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2002; 52(1): 49-57.
5. BROOKS BJ JR, SEIFTER EJ, WALSH TE, LICHTER AS, BUNN PA et al. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. J Clin Oncol 1986; 4(2): 200-209.
6. BURMAN C, KUTCHER GJ, EMAMI B, GOITEIN M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 1991; 21(1): 123-135.
7. BYHARDT RW, MARTIN L, PAJAK TF, SHIN KH, EMAMI B, COX JD. The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC) - analysis of a Radiation Therapy Oncology Group (RTOG) protocol. Int J Radiat Oncol Biol Phys 1993; 27(3): 537-544.
8. BYHARDT RW, SCOTT C, SAUSE WT, EMAMI B, KOMAKI R et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998; 42(3): 469-478.
9. COOPER JS, GUO MD, HERSKOVIC A, MACDONALD JS, MARTENSON JA JR et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281(17): 1623-1627.
10. COX JD, AZARNiA N, BYHARDT RW, SHIN KH, EMAMI B, PAJAK TF. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990; 8(9): 1543-1555.
11. DE GERSEM WR, DERYCKE S, DE WAGTER C, DE NEVE WC. Optimization of beam weights in conformal radiotherapy planning of stage III non-small cell lung cancer: effects on therapeutic ratio. Int J Radiat Oncol Biol Phys 2000; 47(1): 255-260.
12. DILLMAN RO, SEAGREN SL, PROPERT KJ, GUERRA J, EATON WL et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323(14): 940-945.
13. EMAMI B, LYMAN J, BROWN A, COIA L, GOITEIN M et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21(1): 109-122.
14. ENGELSMAN M, REMEIJER P, VAN HERK M, LEBESQUE JV, MIJNHEER BJ, DAMEN EM. Field size reduction enables iso-NTCP escalation of tumor control probability for irradiation of lung tumors. Int J Radiat Oncol Biol Phys 2001; 51(5): 1290-1298.
15. FERREIRA CG, HUISMAN C, GIACCONE G. Novel approaches to the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2002; 41(1): 57-77.
16. FLEMING ID, COOPER JS, HENSON DE. AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1997.
17. GIACCONE G. Clinical impact of novel treatment strategies. Oncogene 2002; 21(45): 6970-6981.
18. GRAHAM MV, JAIN NL, KAHN MG, DRZYMALA RE, PURDY JA. Evaluation of an objective plan-evaluation model in the three dimensional treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1996; 34(2): 469-474.
19. GRAHAM MV, PURDY JA, EMAMI B, HARMS W, BOSCH W et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999; 45(2): 323-329.
20. GRAHAM MV, PURDY JA, EMAMI B, HARMS W, MATTHEWS J. 3-D conformal radiotherapy for lung cancer. The Washington University experience. Front Radiat Ther Oncol 1996; 29: 188-198.
21. HAYMAN JA, MARTEL MK, TEN HAKEN RK, NORMOLLE DP. TODD RF 3rd et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001; 19(1): 127-136.
22. HERNANDO ML, MARKS LB, BENTEL GC, ZHOU SM, HOLLIS D et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 2001; 51(3): 650-659.
23. ICRU-50: Prescribing, Recording, and Reporting Photon Beam Therapy. Ashford: Nuclear Technology Publishing, 1993.
24. JEREMIC B, SHIBAMOTO Y, ACIMOVIC L, MILISAVLJEVIC S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/ etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996; 14(4): 1065-1070.
25. KUTCHER GJ, BURMAN C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys 1989; 16(6): 1623-1630.
26. KWA SL, LEBESQUE JV, THEUWS JC, MARKS LB, MUNLEY MT et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 1998; 42(1): 1-9.
27. LAGERWAARD FJ, SENAN S, VAN MEERBEECK JP, GRAVELAND WJ. Has 3-D conformal radiotherapy (3D CRT) improved the local tumour control for stage I non-small cell lung cancer? Radiother Oncol 2002; 63(2): 151-157.
28. LEE JS, SCOTT C, KOMAKI R, FOSSELLA FV, DUNDAS GS et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06. J Clin Oncol 1996; 14(4): 1055-1064.
29. LYMAN JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 1985; 8: S13-19.
30. LYMAN JT, WOLBARST AB. Optimization of radiation therapy, III: A method of assessing complication probabilities from dose-volume histograms. Int J Radiat Oncol Biol Phys 1987; 13(1): 103-109.
31. LYMAN JT, WOLBARST AB. Optimization of radiation therapy, IV: A dose-volume histogram reduction algorithm. Int J Radiat Oncol Biol Phys 1989; 17(2): 433-436.
32. MAGUIRE PD, MARKS LB, SIBLEY GS, HERNDON JE 2nd, CLOUGH RW et al. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. J Clin Oncol 2001; 19(3): 705-711.
33. MARKS LB, MUNLEY MT, BENTEL GC, ZHOU SM, HOLLIS D et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys 1997; 39(3): 563-570.
34. MARTEL MK, TEN HAKEN RK, HAZUKA MB, TURRISI AT, FRAASS BA, LICHTER AS. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys 1994; 28(3): 575-581.
35. MOUNTAIN CF, LIBSHITZ HI, HERMES KE. Lung cancer handbook for staging and imaging. 2nd ed. Houston: Clifton F. Mountain Foundation, 1997.
36. MUNLEY MT, MARKS LB, SCARFONE C, SIBLEY GS, PATZ EF JR et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer 1999; 23(2): 105-114.
37. NESTLE U, WALTER K, SCHMIDT S, LICHT N, NIEDER C et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 1999; 44(3): 593-597.
38. OETZEL D, SCHRAUBE P, HENSLEY F, SROKA-PEREZ G, MENKE M, FLENTJE M. Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 1995; 33(2): 455-460.
39. QUON H, SHEPHERD FA, PAYNE DG, COY P, MURRAY N et al. The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 1999; 43(1): 39-45.
40. PEREZ CA, PURDY JA, HARMS W, GERBER R, GRAHAM MV et al. Three-dimensional treatment planning and conformal radiation therapy: preliminary evaluation. Radiother Oncol 1995; 36(1): 32-43.
41. ROBERT F, CHILDS HA, SPENCER SA, REDDEN DT, HAWKINS MM. Phase I/IIa study of concurrent paclitaxel and cisplatin with radiation therapy in locally advanced non-small cell lung cancer: analysis of early and late pulmonary morbidity. Semin Radiat Oncol 1999; 9(2): 136-147.
42. ROBNETT TJ, MACHTAY M, VINES EF, MCKENNA MG, ALGAZY KM, MCKENNA WG. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 2000; 48(1): 89-94.
43. RTOG/EORTC Late Radiation Morbidity Scoring Criteria: http://www.rtog.org/members/toxicity/late.html
44. SAUSE WT, SCOTT C, TAYLOR S, JOHNSON D, LIVINGSTON R et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87(3): 198-205.
45. SCHAAKE-KONING C, VAN DEN BOGAERT W, DALESIO O, FESTEN J, HOOGENHOUT J et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326(8): 524-530.
46. SCHILD S, STELLA P, GEYER S, BONNER J, MARKS R et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer(1). Int J Radiat Oncol Biol Phys 2002; 54(2): 370.
47. SCOTT C, SAUSE WT, BYHARDT R, MARCIAL V, PAJAK TF et al. Recursive partitioning analysis of 1592 patients on four Radiation Therapy Oncology Group studies in inoperable non-small cell lung cancer. Lung Cancer 1997; 17(1): S59-74.
48. TEN HAKEN RK, MARTEL MK, KESSLER ML, HAZUKA MB, LAWRENCE TS et al. Use of Veff and iso-NTCP in the implementation of dose escalation protocols. Int J Radiat Oncol Biol Phys 1993; 27(3): 689-695.
49. WIRGEN T. Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer. Radiother Oncol 1997; 44: 9-15.
50. WURSTBAUER K, DEUTSCHMANN H, KRANZINGER M, MERZ F, RAHIM H et al. Radiotherapy for lung cancer: target splitting by asymmetric collimation enables reduction of radiation doses to normal tissues and dose escalation. Int J Radiat Oncol Biol Phys 1999; 44(2): 333-341.
51. YAMADA M, KUDOH S, HIRATA K, NAKAJIMA T, YOSHIKAWA J. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer 1998; 34(1): 71-75.
52. YUEN AR, HALSEY J, FISHER GA, HOLMLUND JT, GEARY RS et al. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res 1999; 5(11): 3357-3363.
53. YUEN AR, SIKIC BI. Clinical studies of antisense therapy in cancer. Front Biosci 2000; 5: 588-593.